289 related articles for article (PubMed ID: 20009575)
1. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract][Full Text] [Related]
2. Two is better than one: benefits of VEGF and PDGF inhibition in ovarian cancer.
Sennino B
Cancer Biol Ther; 2010 Feb; 9(3):183-5. PubMed ID: 20083903
[No Abstract] [Full Text] [Related]
3. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
Kim TJ; Landen CN; Lin YG; Mangala LS; Lu C; Nick AM; Stone RL; Merritt WM; Armaiz-Pena G; Jennings NB; Coleman RL; Tice DA; Sood AK
Cancer Biol Ther; 2009 Dec; 8(23):2263-72. PubMed ID: 19829059
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
Lu C; Kamat AA; Lin YG; Merritt WM; Landen CN; Kim TJ; Spannuth W; Arumugam T; Han LY; Jennings NB; Logsdon C; Jaffe RB; Coleman RL; Sood AK
Clin Cancer Res; 2007 Jul; 13(14):4209-17. PubMed ID: 17634550
[TBL] [Abstract][Full Text] [Related]
5. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.
Sennino B; Falcón BL; McCauley D; Le T; McCauley T; Kurz JC; Haskell A; Epstein DM; McDonald DM
Cancer Res; 2007 Aug; 67(15):7358-67. PubMed ID: 17671206
[TBL] [Abstract][Full Text] [Related]
6. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Lu C; Thaker PH; Lin YG; Spannuth W; Landen CN; Merritt WM; Jennings NB; Langley RR; Gershenson DM; Yancopoulos GD; Ellis LM; Jaffe RB; Coleman RL; Sood AK
Am J Obstet Gynecol; 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PubMed ID: 18395047
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
8. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
[TBL] [Abstract][Full Text] [Related]
9. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.
Falcon BL; Pietras K; Chou J; Chen D; Sennino B; Hanahan D; McDonald DM
Am J Pathol; 2011 Jun; 178(6):2920-30. PubMed ID: 21641409
[TBL] [Abstract][Full Text] [Related]
10. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
11. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma.
Moreno-Smith M; Lee SJ; Lu C; Nagaraja AS; He G; Rupaimoole R; Han HD; Jennings NB; Roh JW; Nishimura M; Kang Y; Allen JK; Armaiz GN; Matsuo K; Shahzad MM; Bottsford-Miller J; Langley RR; Cole SW; Lutgendorf SK; Siddik ZH; Sood AK
Neoplasia; 2013 May; 15(5):502-10. PubMed ID: 23633922
[TBL] [Abstract][Full Text] [Related]
12. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
[TBL] [Abstract][Full Text] [Related]
13. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
[TBL] [Abstract][Full Text] [Related]
14. Proliferation and maturation of intratumoral blood vessels in women with malignant ovarian tumors assessed with cancer stem cells marker nestin and platelet derived growth factor PDGF-B.
Czekierdowska S; Stachowicz N; Chróściel M; Czekierdowski A
Ginekol Pol; 2017; 88(3):120-128. PubMed ID: 28397199
[TBL] [Abstract][Full Text] [Related]
15. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
[TBL] [Abstract][Full Text] [Related]
16. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
Ishikura N; Yorozu K; Kurasawa M; Yanagisawa M; Sugimoto M; Yamamoto K
Oncol Rep; 2019 Sep; 42(3):1057-1065. PubMed ID: 31322247
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer.
Suzuki S; Dobashi Y; Hatakeyama Y; Tajiri R; Fujimura T; Heldin CH; Ooi A
BMC Cancer; 2010 Nov; 10():659. PubMed ID: 21118571
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
19. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
Tao X; Sood AK; Deavers MT; Schmeler KM; Nick AM; Coleman RL; Milojevic L; Gershenson DM; Brown J
Gynecol Oncol; 2009 Sep; 114(3):431-6. PubMed ID: 19524286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
